C0220908||Screening
C0334227||Carcinoma Cells
C1259556||ERCC3
C0080065||MYC
C0235974||Pancreatic Cancer
C1704656||diagnosed
C4255448||metastasis
C1335302||pancreatic ductal adenocarcinoma
C1335302||pancreatic ductal adenocarcinoma
C4282132||devastating malignancy
C3151529||lethality
C0087111||therapies
C0027651||tumors
C3161035||models
C2603343||study
C1335302||pancreatic ductal adenocarcinoma
C1335302||pancreatic ductal adenocarcinoma
C0475358||tumor samples
C0430400||culture
C0430400||culture
C0389995||Rho kinase
C0014432||inhibitor
C0667301||Y-27632
C0522537||patient-derived xenografts
C0522537||patient-derived xenografts
C0220825||evaluated
C1254351||clinical agents
C0220825||evaluated
C1254351||tested agents
C1335302||pancreatic ductal adenocarcinoma
C0430400||cultures
C1254351||Drugs
C0597297||protein turnover
C0040649||transcription
C1336789||transcriptional repressors
C0077274||triptolide
C0243077||covalent inhibitor
C1259556||ERCC3
C1515655||in vivo
C1516747||prolonged complete regression
C0520484||patient-derived xenografts
C3161035||models
C1335302||pancreatic ductal adenocarcinoma
C0087111||therapies
C0077274||triptolide
C0080065||MYC-amplified
C0522537||patient-derived xenografts
C3161035||models
C0080065||oncoprotein MYC
C1158770||transcriptional regulator
C1171362||Expression
C1259556||ERCC3
C0080065||MYC
C1335302||PDACs
C0013203||acquired resistance
C0077274||triptolide
C1259556||ERCC3
C0080065||MYC
C1171362||expression
C3273927||The Cancer Genome Atlas analysis
C1259556||ERCC3
C1171362||expression
C0278252||poor prognosis
C2985437||CDKN2A-null
C0027651||highly proliferative tumors
C0080065||MYC
C1259556||ERCC3
C1335302||pancreatic ductal adenocarcinoma
C3537152||signaling
C0080065||MYC
C0006826||cancers